Darolutamide With Docetaxel and ADT Shows OS Benefit in Metastatic Hormone-Sensitive Prostate Cancer -

In the phase 3 ARASENS study, the use of darolutamide with docetaxel and androgen deprivation therapy demonstrated an overall survival advantage for patients with metastatic hormone-sensitive prostate cancer.